Abstract:This research shows an example that reducing innate immunogenicity to increase payload protein expression of self‐amplifying RNA via a single mutation in the macrodomain. The mutant saRNA attenuates the activation of the double‐stranded RNA sensor as well as the downstream interferon response. It has improved ribosomal RNA stability and reduced cytotoxicity, leading to enhanced payload protein expression. The efficacy and safety of self‐amplifying mRNA (saRNA) have been demonstrated in COVID‐19 vaccine applications. Unlike conventional non‐replicating mRNA (nrmRNA), saRNA offers a key advantage: its self‐replication mechanism fosters efficient expression of the encoded protein, leading to substantial dose savings during administration. Consequently, there is a growing interest in further optimizing the expression efficiency of saRNA. In this study, in vitro adaptive passaging of saRNA is conducted under exogenous interferon pressure, which revealed several mutations in the nonstructural protein (NSP). Notably, two stable mutations, Q48P and I113F, situated in the NSP3 macrodomain (MD), attenuated its mono adenosine diphosphate ribose (MAR) hydrolysis activity and exhibited decreased replication but increased payload expression compared to wild‐type saRNA (wt saRNA). Transcriptome sequencing analysis unveils diminished activation of the double‐stranded RNA (dsRNA) sensor and, consequently, a significantly reduced innate immune response compared to wt saRNA. Furthermore, the mutant saRNA demonstrated less translation inhibition and cell apoptosis than wt saRNA, culminating in higher protein expression both in vitro and in vivo. These findings underscore the potential of reducing saRNA replication‐dependent dsRNA‐induced innate immune responses through genetic modification as a valuable strategy for optimizing saRNA, enhancing payload translation efficiency, and mitigating saRNA cytotoxicity.

Controlling reactogenicity while preserving immunogenicity from a self-amplifying RNA vaccine by modulating nucleocytoplasmic transport

Chronological Management of Adjuvant Effect for Optimized Mrna Vaccine Inspired by Natural Virus Infection.

Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines

Delivery vehicle and route of administration influences self-amplifying RNA biodistribution, expression kinetics, and reactogenicity

Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines

Introduction to RNA Vaccines Post COVID-19

A Novel Self‐Amplifying mRNA with Decreased Cytotoxicity and Enhanced Protein Expression by Macrodomain Mutations

Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer

Complete substitution with modified nucleotides suppresses the early interferon response and increases the potency of self-amplifying RNA

Amplification of Protein Expression by Self-Amplifying mRNA Delivered in Lipid Nanoparticles Containing a β-Aminoester Ionizable Lipid Correlates with Reduced Innate Immune Activation

In Silico Design of a Trans-Amplifying RNA-Based Vaccine against SARS-CoV-2 Structural Proteins

Broad-spectrum immune suppression encoded in self-amplifying RNA enables non-cytotoxic, non-immunostimulatory, reversible transgene expression

Less is more: Self-amplifying mRNA becomes self-killing upon dose escalation in immune-competent retinal cells

Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19

Production, Characterization, and Assessment of Permanently Cationic and Ionizable Lipid Nanoparticles for Use in the Delivery of Self-Amplifying RNA Vaccines

saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern

Improvement of the potency of a N1-methylpseudouridine-modified self-amplifying RNA through mutations in the RNA-dependent-RNA-polymerase

New Generation Self-Replicating RNA Vaccines Derived from Pestivirus Genome

RNA: The new revolution in nucleic acid vaccines

Recent advances in nanoparticulate RNA delivery systems

An inoculation site-retained mRNA vaccine induces robust immune responses against SARS-CoV-2 variants